AIM ImmunoTech Inc. — 2019 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2019; filed March 30, 2020. Amounts below are U.S. dollars. The filing is an annual report, not a quarterly filing.
Business context
AIM is a clinical-stage immunopharmaceutical company developing Ampligen (rintatolimod) for cancer, ME/CFS and viral indications, and Alferon N Injection, a natural-source interferon approved for certain genital-wart uses. Ampligen was not FDA-approved or marketed in the United States. It had approval in Argentina for severe ME/CFS, but commercial launch preparations were still underway. Alferon’s U.S. sales were halted because the company lacked finished product inventory.
Financial results and liquidity
| Metric | 2019 | 2018 |
|---|---|---|
| Revenue | $140,000 | $367,000 |
| Operating loss | $12.443 million | $11.496 million |
| Net loss | $9.533 million | $9.827 million |
| Basic and diluted loss per share | $2.62 | $9.77 |
| Cash used in operating activities | $9.067 million | $10.640 million |
| Cash and cash equivalents at year-end | $1.470 million | $299,000 |
| Marketable securities at year-end | $7.308 million | $1.526 million |
- Revenue came from Ampligen clinical treatment programs in the U.S. and Europe; the company reported no Alferon finished goods available for commercial sale. Revenue fell 62%, largely because clinical sites had built inventory in late 2018.
- Total costs and expenses rose to $12.583 million from $11.863 million. R&D declined 3% to $4.651 million, while G&A rose 14% to $7.039 million. Production costs were $893,000.
- Operating loss widened despite a slightly lower net loss. The net result included a $1.510 million non-cash gain from redeemable-warrant revaluation, a $776,000 gain from sale of New Jersey tax losses, and a $1.217 million insurance-claim gain. The filing also reports a $90,000 convertible-note fair-value gain and a $345,000 debt-extinguishment loss.
- Year-end current assets were $10.446 million and current liabilities $1.127 million, for working capital of approximately $9.319 million. Total assets were $20.219 million; stockholders’ equity was $12.907 million.
- Debt and financing obligations included $3.910 million of notes payable and a $2.318 million sale-leaseback financing obligation. The notes issued in 2019 carried 10% interest and were secured by substantially all assets other than intellectual property. Operating lease liabilities were $152,000.
- Financing provided $16.385 million of net cash in 2019, principally from securities sales and borrowing. The company raised approximately $4.69 million in a March rights offering and approximately $8 million in a September public offering; it also used an equity distribution agreement.
- Shares outstanding increased from 1,107,607 at year-end 2018 to 10,386,754 at year-end 2019. The filing reports 27,626,077 shares outstanding as of March 27, 2020.
Material changes and developments
- Operating loss increased by approximately $947,000 as expenses outpaced the reduced revenue. Lower R&D spending was more than offset by higher G&A.
- The company’s reported net loss narrowed by $294,000, but was affected by non-cash valuation gains and other unusual gains and losses; it should not be read as evidence of improved operating profitability.
- In 2019 AIM amended and partly converted its Iliad convertible debt, then paid it off in December using proceeds from a new Atlas Sciences secured note. It also issued a $2.635 million principal secured note to Chicago Venture Partners in August.
- In the first three months of 2020, the company reported approximately $25.6 million of cash proceeds: about $16.712 million net from ATM stock sales and $8.658 million from warrant exercises. These financings materially increased liquidity but involved further share issuance.
- AIM completed a 44-for-1 reverse stock split in June 2019. The filing’s stated share counts and per-share figures reflect the split unless otherwise indicated.
Outlook, risks and unusual items
- Management’s priorities included pursuing U.S. and international commercialization, seeking co-development partners, advancing clinical programs, and preparing manufacturing operations. No revenue or profitability guidance was provided.
- The company reported six Ampligen cancer trials underway and described additional 2020 trials as planned, subject to funding. It was awaiting a comprehensive report on the Dutch pancreatic-cancer early-access program, in which 42 patients had received Ampligen by year-end 2019.
- The FDA issued a Complete Response Letter for the Ampligen ME/CFS NDA in 2013, citing insufficient evidence of efficacy and an inadequate safety database, and requested additional work. U.S. approval remains uncertain.
- Management was investigating Ampligen as a possible COVID-19 treatment or prophylactic, including planned in-vitro testing in Japan and discussions or initiatives involving China and other countries. The filing stresses that efficacy in humans is unproven and that additional testing and trials are required.
- COVID-19 could disrupt patient enrollment, clinical sites, shipping, regulatory reviews and company operations; management said the full impact could not be estimated. The company also noted that pandemic-related work could redirect resources from other programs.
- Alferon manufacturing was on hold, with no definitive restart timetable. The filing estimates approximately $10 million would be needed to resume manufacturing and prepare for FDA pre-approval inspection; required funding and regulatory clearance are not assured.
- AIM disclosed substantial historical losses, an accumulated deficit of $328.109 million, and a continuing need for financing. Management said it believed actions had alleviated substantial doubt about continuing as a going concern, but warned that additional funding may be needed and may not be available.
- Other risks include product-development and regulatory uncertainty, dependence on third-party manufacturers and partners, potential dilution, limited product-liability insurance, and volatile trading. The BioLife contract dispute remained pending; BioLife asserted a $96,676 counterclaim, which AIM denied.
- The auditor issued an unmodified opinion on the financial statements. Management reported effective disclosure controls and internal control over financial reporting, with no material weaknesses identified.
Most important facts for investors to verify
- Whether 2020 financing proceeds and subsequent share issuance provide adequate runway, and the resulting dilution and fully diluted share count.
- Current cash, marketable securities, operating cash burn, debt balances, security interests and repayment terms after the 2020 financings.
- Progress and commercial economics of the Argentina Ampligen launch, including manufacturing release, reimbursement and actual sales.
- FDA requirements and funding needs for the Ampligen NDA, and the status of clinical trials and the Dutch pancreatic-cancer data.
- Whether Alferon manufacturing can be funded, revalidated and cleared for commercial production, given the stated estimated cost and lack of timetable.
- Whether COVID-19 research produces credible clinical evidence and how pandemic disruptions affect trials, manufacturing and cash needs.